HEMATOLOGIC AND BIOCHEMICAL INDICATORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2019.2.10578Keywords:
chronic obstructive pulmonary disease, hypertension, comorbidity, blood indicatorsAbstract
The aim of the work. To analyse laboratory indicators of general clinical and biochemical blood analysis in patients with comorbid course of chronic obstructive pulmonary disease and hypertension.
Materials and Methods. The study involved 53 patients with COPD, 28 of them had arterial hypertension and were hospitalized. Indicators of the total blood test were performed on an automatic hematology analyser, indicators of biochemical analysis of blood were determined using standard sets on the automatic biochemical analyser COBAS INTEGRA company.
Results and Discussion. No pathological changes were observed in the study of indicators of general blood analysis in patients with COPD and with the combined course of COPD and hypertension. It should be noted a significantly higher percentage of eosinophils and erythrocyte sedimentation rate in COPD patients relative to the control group. In the analysis of glucose level it was found that its concentration was significantly higher (by 29.5 %) with the combined course of COPD and AH against control group. Total protein content in patients in the experimental groups tended to decrease, but was not statistically significantly different from the control data. Possibly higher concentration of urea and creatinine in patients with comorbid course of COPD and AH. The average levels of blood electrolytes (sodium and potassium) in patients with comorbid COPD and AH met the requirements, while the calcium concentration has significantly decreased (by 47.6 %) as regards control.
Conclusions. The comorbid course of chronic obstructive pulmonary disease and arterial hypertension is characterized by impaired protein (higher levels of urea and creatinine) and carbohydrate (higher glucose concentration in control) metabolism, electrolyte imbalance (decrease in calcium level) in control.
References
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2095-128. DOI: https://doi.org/10.1016/S0140-6736(12)61728-0
Afonso AS, Verhamme KM, Sturkenboom MC, Brusselle GG. COPD in the general population: prevalence, incidence and survival. Respir Med. 2011;105(12): 1872-84. DOI: https://doi.org/10.1016/j.rmed.2011.06.012
Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest. 2007;131(1): 29-36. DOI: https://doi.org/10.1378/chest.06-0365
Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019;15(1): 24-35 doi: 10.1183/20734735.0346-2018. DOI: https://doi.org/10.1183/20734735.0346-2018
Raherison C, Ouaalaya EH, Bernady A, Casteigt J, Nocent-Eijnani C, Falque L, Le Guillou F, et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med. 2018;18(1): 117 doi: 10.1186/s12890-018-0684-7. DOI: https://doi.org/10.1186/s12890-018-0684-7
Kanovska LV, Kaushanska OV, Trefanenko IV, Tkach YP. Role of separate pathogenetic mechanisms in forming of chronic obstructive pulmonary disease and ischemic heart disease. Young Scientist. 2015;5(20): 23-6.
Todorico LD. [Chronic obstructive pulmonary disease in ischemic heart disease and arterial hypertension]. Tuberkulioz, lehen khvorob, VIL-infekts. 2013;1(12): 102-08. Ukrainian.
Yatsenko OV. [Comparative characterization of the level of indicators of matrix metalloproteinase-9 and highly sensitive C-reactive protein in the comorbid course of hypertension and chronic obstructive pulmonary disease]. Scientific Journal “Science Rise: Medical Science”. 2017;5(13): 32-6. Ukrainian. DOI: https://doi.org/10.15587/2519-4798.2017.102579
Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016. Available from: www.goldcopd.org.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33): 3021-104. DOI: https://doi.org/10.1093/eurheartj/ehy339
Krivenko VV. [Systemic inflammation and morphofunctional parameters of myocardium and blood vessels in patients with combined course of chronic obstructive pulmonary disease and hypertension]. Zaporizh med zhurn. 2013;3(78): 43-6. Ukrainian.
Vydyborets SV, Kucher OV, Serhiienko OV. [Clinical significance of changes in the rate of erythrocyte sedimentation rate]. Zdorovia susp. 2013;2: 85-92. Ukrainian. DOI: https://doi.org/10.22141/2306-2436.2.2.2013.121767
Remennyk OI. [Clinical significance of the study of glucose content in erythrocytes of patients with chronic pulmonary heart]. Semeynaya meditsina. 2013;6(50): 24-6. Ukrainian.
Agarwal K, Sharma L, Menon B, Gaur SN. Comparison of nutritional status in chronic obstructive pulmonary disease and asthma. Indian J Allergy, Asthma and Immunol. 2013;27(2): 115. DOI: https://doi.org/10.4103/0972-6691.124393
Toppo A, Sudheer D, Rajawat GS, Kurian T. A study to assess nutritional profile in chronic obstructive pulmonary disease patients. Int J Adv Med. 2017;4(2): 450-6. DOI: https://doi.org/10.18203/2349-3933.ijam20171040
Dilektaşli AG, Ulubay G, Bayraktar N, Eminsoy I, Eyüboğlu FO. The effects of cachexia and related components on pulmonary functions in patients with COPD. Tuberk Toraks. 2009;157(3): 298-305.
Rashid ur H. Electrolyte disturbances in acute exacerbation of COPD. J Enam Med Col. 2019;9(1): 25-9. DOI: https://doi.org/10.3329/jemc.v9i1.39900
Avdeev SN. [Chronic obstructive pulmonary disease as a systemic disease]. Pulmonol. 2007;2: 104-12. Russian.
Vertkin AL, Skotnikov AS, Gubzhokova OM. [Comorbidity in chronic obstructive pulmonary disease: the role of chronic systemic inflammation and the clinical and pharmacological niches of roflumilast]. Lechashchiy vrach. 2013;9: 20-5. Russian.
Marushchak MI. [Changes in blood gas composition in experimental acute lung injury in dynamics]. Zdobut klin i eksperem med. 2011;1: 75-8. Ukrainian.
Ovcharenko SI, Nersesyan ZN, Morozova TE. [Chronic obstructive pulmonary disease in combination with hypertension: the efficacy and safety of prolonged action of indapamide]. Sistem gipertenzii. 2014;2: 54-8. Russian. DOI: https://doi.org/10.26442/SG29026
Pavlenko VI, Naryshkina SV. [Features of the state of the oxidant-antioxidant system in chronic obstructive pulmonary disease combined with coronary heart disease]. Profilakt med. 2012;1: 75. Russian.
